天津博爱新开源国际贸易有限公司

Boai NKY Medical Holdings Ltd (NKY, stock code: 300109), a publicly traded company on the Shenzhen Stock Exchange, is the first domestic enterprise to develop and produce PVP and PVM/MA products, ranking as the third largest global PVP manufacturer. Its product lines include KoVidone® and PolyKoVidone® series, which represent povidone, crospovidone, and copovidone pharmaceutical excipients. KoVidone®-I (PVP-I) is a broad-spectrum biocide, fungicide, and virucide. The OraRez® series represents functional polymers for bioadhesive/mucoadhesive applications. NKY also provides pharmaceutical solvents and intermediates. As the first Chinese manufacturer to obtain EXCiPACTTM GMP certification, NKY adheres to strict cGMP guidelines, handling and packaging all pharmaceutical products in Class D cleanrooms. The company’s advanced manufacturing facility, fully validated QC equipment and test methods, and full audit trail compliance ensure high-quality standards. Environmentally responsible, NKY complies with government requirements, monitors waste streams in real time, recycles 100% of processing water, converts entirely to natural gas, and focuses on green production processes. The Technical Research Center supports customers with formulation development, operates a new R&D center commissioned in 2018 that integrates R&D and pilot manufacturing, partners with customers to explore new opportunities, and offers strong customer and quality management services.